Usage of potent CYP1A2 inhibitors needs to be discontinued ahead of initiating pirfenidone and prevented through treatment; if robust CYP1A2 inhibitors are the sole drug of selection, dosage reductions are advisable phenobarbital will lessen the extent or outcome of pirfenidone by affecting hepatic enzyme CYP1A2 metabolism. Contraindicated. Utilization of robust https://jamesc332pam5.hamachiwiki.com/user